Severe Allergic Dysregulation Due to A Gain of Function Mutation in the Transcription Factor STAT6

Safa Baris,Mehdi Benamar,Qian Chen,Mehmet Cihangir Catak,Mónica Martínez-Blanco,Muyun Wang,Jason Fong,Asena Pinar Sefer,Altan Kara,Royala Babayeva,Sevgi Bilgic Eltan,Ayse Deniz Yucelten,Emine Bozkurtlar,Leyla Cinel,Elif Karakoc-Aydiner,Yumei Zheng,Hao Wu,Ahmet Ozen,Klaus Schmitz-Abe,Michel J. Massaad,Talal A. Chatila
DOI: https://doi.org/10.1016/j.jaci.2023.01.023
IF: 14.29
2023-02-09
Journal of Allergy and Clinical Immunology
Abstract:Background Inborn errors of immunity (IEI) have been implicated in causing immune dysregulation, including allergic diseases. The signal transducer and activator of transcription 6 (STAT6) is a key regulator of allergic responses. Objective We sought to characterize a novel gain-of-function (GOF) STAT6 mutation identified in a child with severe allergic manifestations. Methods We performed whole-exome and targeted gene sequencing, lymphocyte characterization, and molecular and functional analyses of mutated STAT6. Results We report a child with a missense mutation in the DNA binding domain of STAT6 (c.1114G>A, p.E372K) who presented with severe atopic dermatitis, eosinophilia and elevated IgE. Naive lymphocytes from the affected patient displayed increased T H 2 and suppressed T H 1 and T H 17 cell responses. The mutation augmented both basal and cytokine-induced STAT6 phosphorylation without affecting dephosphorylation kinetics. Treatment with the Janus kinase 1/2 inhibitor ruxolitinib reversed STAT6 hyperresponsiveness to IL-4, normalized T H 1, and T H 17, suppressed the eosinophilia and improved the patient's atopic dermatitis. Conclusions We identified a novel IEI due to STAT6 GOF mutation that gave rise to severe allergic dysregulation. Janus kinase inhibitor therapy could represent an effective targeted treatment for this disorder.
immunology,allergy
What problem does this paper attempt to address?